<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090917</url>
  </required_header>
  <id_info>
    <org_study_id>7886</org_study_id>
    <nct_id>NCT05090917</nct_id>
  </id_info>
  <brief_title>Growth Curves in Cockayne Syndrome Type 1 and Type 2</brief_title>
  <acronym>Curves-CS</acronym>
  <official_title>Development of Growth Curves in Cockayne Syndrome Type 1 and Type 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the natural progression of Cockayne's syndrome, affected patients also present with&#xD;
      variable neurological and gastrointestinal damage (gastroesophageal reflux, recurrent&#xD;
      vomiting, swallowing disorders, etc.) with varying repercussions on their growth. Acute&#xD;
      intercurrent events such as seizures, constipation, infections can also interact with their&#xD;
      metabolism, food intake and influence their growth. The nutritional deficit potentially&#xD;
      involved in this growth retardation can be responsible for many manifestations such as&#xD;
      anemia, bone fractures, fatigue, coagulation disorders responsible in total for the reduction&#xD;
      in quality and life expectancy.&#xD;
&#xD;
      Faced with growth retardation in patients with Cockayne syndrome, medical management is&#xD;
      difficult to establish. Is this delay part of the natural course of the pathology?&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">May 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective study of growth in Cockayne syndrome type 1 and type 2</measure>
    <time_frame>Files analysed retrospectively from January 01, 1985 to March 01, 2020 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Cockayne Syndrome, Type I and II</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Minor patient with cockayne syndrome with molecular confirmation, treated between&#xD;
        01/01/1985 and 01/03/2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Minor patient&#xD;
&#xD;
          -  Cockayne syndrome with molecular confirmation, treated between 01/01/1985 and&#xD;
             01/03/2020&#xD;
&#xD;
          -  Collection of at least one growth data (height, weight, head circumference) for a&#xD;
             given age&#xD;
&#xD;
          -  Clinic compatible with type 1 or 2 Cockayne syndrome&#xD;
&#xD;
          -  Holder of parental authority not opposing, after information, the reuse of their&#xD;
             child's medical data for the purposes of this scientific research.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Refusal to participate in the study.&#xD;
&#xD;
          -  Lack of molecular confirmation of Cockayne syndrome&#xD;
&#xD;
          -  Lack of growth data for a given age.&#xD;
&#xD;
          -  Clinic not compatible with type 1 or 2 Cockayne syndrome. Exclusion of type 3 Cockayne&#xD;
             syndromes, trichothiodystrophy and xeroderma-pigmentosum.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent LAUGEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Pédiatrie1 - Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent LAUGEL, MD, PhD</last_name>
    <phone>33 3 88 12 77 43</phone>
    <email>vincent.laugel@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Pédiatrie1 - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent LAUGEL, MD, PhD</last_name>
      <phone>33 3 88 12 77 43</phone>
      <email>vincent.laugel@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Vincent LAUGEL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah BAER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas TUZIN, Statistician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cockayne Syndrome</keyword>
  <keyword>Cockayne Syndrome, Type I and II</keyword>
  <keyword>Growth curves</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cockayne Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

